eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines and NCCN Templates Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Cancer-Related Fatigue. These NCCN Guidelines^® are currently available as Version 1.2022.

Link directly to the Updates section of the NCCN Guidelines: 
Cancer-Related Fatigue

• Standards of Care (FT-2) Heading 1
  • Bullet 7 revised: Consider referral to an appropriate specialist or supportive care provider (eg, survivorship, palliative care, integrative oncology, psychology, psychiatry, physical therapy, occupational therapy, physical medicine).
• Interventions for Patients on Active Treatment/Nonpharmacologic (FT-6)
  • Footnote o revised: Bright white light therapy of 1250–10,000 lux is most frequently self-administered in the early morning for 30–90 minutes. Timing needs to be adjusted for those who sleep during the day.
• Interventions for Patients Post-Treatment/Nonpharmacologic (FT-7)
  • Bullet 3 revised: "CBT for sleep" changed to "CBT for insomnia (CBT-I)."
• Interventions for Patients at the End of Life/Nonpharmacologic (FT-8)
  • Footnote r added: A structured exercise protocol depending on the patient's tolerance level can be used to improve fatigue experienced by patients with advanced cancer in hospice care (Vira P, et al. Am J Hosp Palliat Care 2021;38:503-511).

NCCN has published updates to the NCCN Guidelines for Testicular Cancer. These NCCN Guidelines are currently available as Version 2.2022.

Link directly to the Updates section of the NCCN Guidelines: 
Testicular Cancer 

• The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Hodgkin Lymphoma to reflect the currently published NCCN Guidelines for Hodgkin Lymphoma v1.2022.

• The following New NCCN Templates^® have been published:
  • HDL66: GVD (Gemcitabine/VinORELBine/Liposomal DOXOrubicin) + Pembrolizumab
  • HDL67: GCD (Gemcitabine/CISplatin/Dexamethasone)
  • HDL68: CVbP (Cyclophosphamide/VinBLAStine/PrednisoLONE) + RiTUXimab
• Changes to the Indication section have been updated on the following templates:
  • HDL1: ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) - Stage I-II Favorable
  • HDL2: ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Stage I-II Unfavorable
  • HDL3: ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Stage III-IV
  • HDL6: Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/ VinCRIStine/PredniSONE/Procarbazine) – Stage III-IV
  • HDL11: Mini-BEAM (Carmustine/Etoposide/Cytarabine/Melphalan)
  • HDL12: MINE (Mesna/Ifosfamide/MitoXANTRONE/Etoposide)
  • HDL17: ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) + RiTUXimab
  • HDL25: C-MOPP – Schema I (Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine)
  • HDL26: C-MOPP – Schema II (Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine)
  • HDL31: Brentuximab vedotin
  • HDL32: Bendamustine
  • HDL46: Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/ VinCRIStine/PredniSONE/Procarbazine) – Stage I-II
  • HDL47: Everolimus
  • HDL48: Lenalidomide
  • HDL50: Brentuximab vedotin + AVD (DOXOrubicin/VinBLAStine/Dacarbazine) – Stage III-IV
  • HDL54: Nivolumab
  • HDL55: Pembrolizumab
  • HDL62: Bendamustine/CARBOplatin/Etoposide
  • HDL63: GEMOX (Gemcitabine/OXALIplatin)
  • HDL64: Brentuximab vedotin followed by AVD (DOXOrubicin/VinBLAStine/Dacarbazine) – Older Adults
• References have been updated on the following templates:
  • HDL1: ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) - Stage I-II Favorable
  • HDL2: ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Stage I-II Unfavorable
  • HDL6: Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/ VinCRIStine/PredniSONE/Procarbazine) – Stage III-IV
  • HDL17: ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) + RiTUXimab
  • HDL25: C-MOPP – Schema I (Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine)
  • HDL26: C-MOPP – Schema II (Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine)
  • HDL46: Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/ VinCRIStine/PredniSONE/Procarbazine) – Stage I-II
  • HDL50: Brentuximab vedotin + AVD (DOXOrubicin/VinBLAStine/Dacarbazine) – Stage III-IV
  • HDL54: Nivolumab
• Changes to the Emetic Risk section have been made on the following templates:
  • HDL8: ICE (Ifosfamide/CARBOplatin/Etoposide)
  • HDL15: IGEV (Ifosfamide/Gemcitabine/VinORELBine/PredniSONE)
  • HDL41: IGEV (Ifosfamide/Gemcitabine/VinORELBine/PredniSONE) + RiTUXimab
  • HDL52: Brentuximab vedotin + Bendamustine
• Changes to the Chemotherapy Regimen section have been made to the following templates:
  • HDL3: ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Stage III-IV
  • HDL6: Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/ VinCRIStine/PredniSONE/Procarbazine) – Stage III-IV
  • HDL31: Brentuximab vedotin
  • HDL46: Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/ VinCRIStine/PredniSONE/Procarbazine) – Stage I-II
  • HDL57: AVD (DOXOrubicin/VinBLAStine/Dacarbazine) – Older Adults
• Drug information notes for the following agents have been updated in the Chemotherapy Regimen, Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • Carmustine
  • Liposomal DOXOrubicin

NCCN has published the NCCN Guidelines, the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), and the NCCN Compendium® for Malignant Peritoneal Mesothelioma. These NCCN Guidelines are new and currently available as Version 1.2022.


 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please  note:  1. Third Party Content. The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content FTP site: ftp://ftp1.nccn.org (To access: user name:content; password is NCCNcontent) (“Third Party Content”). Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.